Latest Cryo-Cell Intl Inc (CCEL) Headlines Cr
Post# of 10
Posted On: 03/09/2014 6:15:12 AM
Latest Cryo-Cell Intl Inc (CCEL) Headlines
Cryo-Cell International swings up to net income of USD27,000 in fiscal 2013
M2 - Tue Mar 04, 6:36AM CST
Cord blood bank company Cryo-Cell International (Other OTC:CCEL) on Monday declared a net income of USD27,000 (USD0.00 per basic and diluted share) for its fiscal year 2013.
Cryo-Cell Reports Financial Results for Fiscal 2013
GlobeNewswire - Mon Mar 03, 4:30PM CST
Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for its fiscal year 2013.
Cryo-Cell Reports Third Quarter 2013 Results
GlobeNewswire - Tue Oct 15, 4:30PM CDT
Cryo-Cell International, Inc. (the "Company") (OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for the fiscal third quarter ended August 31, 2013.
OTC Daily Alert Stock Watch - Cryo-Cell International, Inc (OTCQB: CCEL)
WorldStockWire - Tue Sep 17, 7:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Cryo-Cell Reports Second Quarter 2013 Results
GlobeNewswire - Mon Jul 15, 4:00PM CDT
Cryo-Cell International, Inc. (OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for the second quarter ended May 31, 2013.
Cryo-Cell Reports First Quarter 2013 Results
GlobeNewswire - Fri Apr 05, 7:00AM CDT
Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for the first quarter ended February 28, 2013.
Cryo-Cell International Affiliate Earns Patent for Processing Umbilical Cord Blood for Therapeutic Use in Treating Neurodegenerative Diseases and Spinal Cord and Brain Injuries
GlobeNewswire - Fri Mar 15, 5:00AM CDT
A patent issued to Saneron CCEL Therapeutics, Inc. and the University of South Florida may facilitate increased use of cord blood stem cells in medical therapies, according to Linda Kelley, Ph.D., chief scientific officer with Cryo-Cell International (OTCQB:CCEL). Cryo-Cell is a major investor in Saneron CCEL Therapeutics, a Tampa, Fla.-based research firm with rights to 20 patents related to their cellular therapy technology.
Study Shows Promising Results Using Cord Blood Stem Cells to Treat Cerebral Palsy
GlobeNewswire - Tue Jan 08, 9:43AM CST
(OTCQB:CCEL) Cryo-Cell International Chief Scientific Officer Linda L. Kelley, PhD, expressed optimism that an effective treatment for cerebral palsy (CP) using cord blood stem cells may be on the horizon now that the first results of a Phase 2 study have been published. The paper by Dr. Min Young Kim and colleagues is the first to demonstrate efficacy using umbilical cord blood as therapy in a large, placebo-controlled, double-blind study in South Korea.
Cryo-Cell International swings up to net income of USD27,000 in fiscal 2013
M2 - Tue Mar 04, 6:36AM CST
Cord blood bank company Cryo-Cell International (Other OTC:CCEL) on Monday declared a net income of USD27,000 (USD0.00 per basic and diluted share) for its fiscal year 2013.
Cryo-Cell Reports Financial Results for Fiscal 2013
GlobeNewswire - Mon Mar 03, 4:30PM CST
Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for its fiscal year 2013.
Cryo-Cell Reports Third Quarter 2013 Results
GlobeNewswire - Tue Oct 15, 4:30PM CDT
Cryo-Cell International, Inc. (the "Company") (OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for the fiscal third quarter ended August 31, 2013.
OTC Daily Alert Stock Watch - Cryo-Cell International, Inc (OTCQB: CCEL)
WorldStockWire - Tue Sep 17, 7:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Cryo-Cell Reports Second Quarter 2013 Results
GlobeNewswire - Mon Jul 15, 4:00PM CDT
Cryo-Cell International, Inc. (OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for the second quarter ended May 31, 2013.
Cryo-Cell Reports First Quarter 2013 Results
GlobeNewswire - Fri Apr 05, 7:00AM CDT
Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for the first quarter ended February 28, 2013.
Cryo-Cell International Affiliate Earns Patent for Processing Umbilical Cord Blood for Therapeutic Use in Treating Neurodegenerative Diseases and Spinal Cord and Brain Injuries
GlobeNewswire - Fri Mar 15, 5:00AM CDT
A patent issued to Saneron CCEL Therapeutics, Inc. and the University of South Florida may facilitate increased use of cord blood stem cells in medical therapies, according to Linda Kelley, Ph.D., chief scientific officer with Cryo-Cell International (OTCQB:CCEL). Cryo-Cell is a major investor in Saneron CCEL Therapeutics, a Tampa, Fla.-based research firm with rights to 20 patents related to their cellular therapy technology.
Study Shows Promising Results Using Cord Blood Stem Cells to Treat Cerebral Palsy
GlobeNewswire - Tue Jan 08, 9:43AM CST
(OTCQB:CCEL) Cryo-Cell International Chief Scientific Officer Linda L. Kelley, PhD, expressed optimism that an effective treatment for cerebral palsy (CP) using cord blood stem cells may be on the horizon now that the first results of a Phase 2 study have been published. The paper by Dr. Min Young Kim and colleagues is the first to demonstrate efficacy using umbilical cord blood as therapy in a large, placebo-controlled, double-blind study in South Korea.
(0)
(0)